About Henlius-Management Team

Wenjie Zhang

Chairman
Executive Director and CEO

Mr. Wenjie Zhang is Chairman, Executive Director and Chief Executive Officer of the Company.

Mr. Zhang has 25 years of commercial experience in the pharmaceutical industry. Before joining Henlius in March 2019, he was the Executive Director, Marketing for Amgen Japan and Asia Pacific region at first and then being promoted as General Manager of Amgen China where he was leading company’s overall efforts in expanding business into Chinese market and help Chinese patients to access Amgen’s innovative medicines. During his tenure as General Manager, Amgen China has effectively built up its commercial infrastructure, organization, and competency. He successfully launched Repatha^® (evolocumab), Amgen’s first product in China. Prior to Amgen, Mr. Zhang worked as Vice President, Oncology for Roche in Shanghai, China, where he was managing a strong team of 850 sales and marketing staff in the oncology franchise marketing business unit. He significantly grew the Roche oncology portfolio including Avastin^® (bevacizumab), Tarceva^®(erlotinib) and MABTHERA^® (rituximab) in the China market. He also led Roche China oncology franchise in pipeline planning, franchise strategy, and franchise marketing. Before then, Mr. Zhang served as the head of Business Development at Bayer Schering Pharma, Asia Pacific Headquarters, Product Manager of US Marketing, Business Development Manager and Deputy Director of Global Marketing at Bayer Pharmaceuticals USA. In this role, he led the fastest growing business unit within Bayer China. He also had dual responsibility as Head of the same business unit for Asia Pacific region. He succeeded in launching multiple products in China including Nexavar, Kogenate and Betaferon. Mr. Zhang obtained his MBA from the Yale University School of Management in 1998. He graduated with a B.S. in microbiology from Shandong University in Jinan, China in 1990.
Jason Zhu

President

Mr. Jason Zhu, President of the Company, is responsible for the company’s global product development and management of certain functional departments.Jason has more than 20 years in clinical research industry. He had cooperated with over 70 China local pharmaceutical and biotech companies and led the design and execution of over 100 phase I to IV clinical trials. Prior to joining Henlius, Jason was Founder and CEO of PPC China, Global Vice President of IQVIA, China GM of Omnicare. Jason had previously worked as a physician in Huashan Hospital for two years. Jason holds a bachelor degree in Clinical Medicine form Shanghai Medical College of Fudan University and an EMBA degree from CKGSB.
Wei Huang

Chief Operation Officer
SVP

Ms. Wei Huang, Chief Operation Officer and Senior Vice President, responsible for commercialized production and delivery, and construction of Songjiang Site. Ms. Huang holds Bachelor degree from East China University of Science and Technology in Biochemical Engineering, Master degree from University of Maryland in Chemical and Biochemical Engineering. Prior to joining Henlius, Ms. Huang has Senior management and leadership experience in pharmaceutical and biotechnology industry spanning over twenty-five years in process development, technology transfer, manufacturing, process and facility design, capital project execution, and quality system implementation.
James Guo

SVP

Mr. James Guo, Senior Vice President, graduated from Genetics and Genetic Engineering Department of Fudan University, and holds a MBA degree from Zhejiang University. He has previously served as research manager, vice president and chief engineer in Hangzhou Jiuyuan Gene Engineering Co., Ltd., Hangzhou Taishi Biotechnology Co., Ltd., Zhejiang Cifu Pharmaceutical Co. and Shanghai Chemo Wanbang Biopharma Co., Ltd. James is experienced in biopharmaceutical development and production, and familiar with all types of national laws and regulations. He has been involved in the development of a Category II new drug which is the first listed recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection in China. He was awarded Outstanding Technology Development Talent of Hangzhou, Second Prize for Science and Technology Progress Award of Zhejiang Province and First Prize for Science and Technology Progress Award of Hangzhou. In addition, he is the vice-chairman of Shanghai Biopharmaceutics Industry Association Monoclonal Antibody Drug Professional Committee currently.
Jean-Michel Gries

President of Hengenix Biotech

Dr. Jean-Michel Gries, President of Hengenix Biotech, Inc.,directs Hengenix day-to-day operation and oversees Henlius global research function.

Dr. Gries has over 20 years of professional and managerial experience in clinical pharmacology and early research, with robust knowledge of a broad set of disease areas. He also has successful experience in operation management, licensing, and R&D strategy design. Before joining Henlius, Dr. Gries has served as the director of Clinical Pharmacology at Aventis (now SANOFI), the head of Clinical Pharmacology at Roche US, VP, CSO&CMO at Paramount Biosciences, the head of R&D at ALCON/Novartis, the General Manager of Early Clinical Development at Covance, and General Manager of Early Phase at Parexel, and the Chief R&D Officer at Kodikaz Therapeutic Solutions. Dr. Gries has a PharmD and a PhD in Pharmacokinetic from Rene Descartes University in Paris, a PhD in Analytical Chemistry, and a Master in Statistics from Paris-Sud University (Paris XI). He also obtained his MBA degree from the Wharton School of the University of Pennsylvania.
Gino Li

Chief Financial Officer
VP

Mr. Gino Li, Chief Financial Officer and Vice President, is responsible for listing investment management, market value management and financial operation management. Previously, Mr. Li served as vice president and the general manager of investor relations and capital development department of Fosun Pharma. Mr. Li obtained a Bachelor of Science degree in Pharmacy from Sichuan University in 2004, a Master of Science degree from the University of Huddersfield in the U.K. in 2006, and a master’s degree from the IMBA Programme of Fudan University – Hong Kong University in 2016.
Kurt Yu

Chief Commercial Officer
VP

Mr. Kurt Yu, Chief Commercial Officer and Vice President of the Company, leads the marketing team and is responsible for the marketing strategy development, new product launch preparation, marketing activity planning and execution. He also takes charge of Pricing and Market Access, Distribution Management, Medical Affairs and Key Account, etc. Prior to joining Henlius, Mr. Yu has over 20 years’ experience in sales and central marketing management (for Glaxo Wellcome, Roche and Amgen) with different roles including medical representative, product manager, district sales manager, marketing manager, and marketing director/ head. He has rich experience in portfolio management, marketing strategy development, new product launch etc.

Mr. Yu graduated from Shanghai Medical University with bachelor degree in pharmaceutical chemistry. Then he obtained the EMBA degree from Fudan University.
Ping Cao

VP of Business Development

Ms. Ping Cao, Vice President of Business Development, graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and also obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro,Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Then Ms. Cao joined business development team focusing on technology transactions. She negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.
Wallis Zeng

VP of Sales

Mr. Wallis Zeng, Vice President of Sales, graduated from Gannan Medical University, majoring in clinical medicine.

Mr. Zeng is responsible for the sales strategy development, establishing and leading the sales team to achieve the annual sales targets. Prior to joining Henlius, he served as regional sales manager at MSD, national sales director at Roche, general manager at Evergrande Health and sales director at AZ. So far, he has about 30 years’ working experience. Mr. Zeng has rich experience in sales strategy development and sales team management.